ATAI Life Sciences NV (ATAI)
2.11
+0.06
(+2.93%)
USD |
NASDAQ |
May 06, 16:00
2.18
+0.07
(+3.32%)
Pre-Market: 08:11
ATAI Life Sciences Cash from Operations (TTM): -84.12M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -84.12M |
| September 30, 2023 | -92.66M |
| June 30, 2023 | -102.28M |
| March 31, 2023 | -101.59M |
| December 31, 2022 | -104.47M |
| September 30, 2022 | -94.47M |
| June 30, 2022 | -94.54M |
| Date | Value |
|---|---|
| March 31, 2022 | -70.71M |
| December 31, 2021 | -63.25M |
| September 30, 2021 | -48.95M |
| June 30, 2021 | -26.29M |
| March 31, 2021 | -33.40M |
| December 31, 2020 | -20.77M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-104.47M
Minimum
Dec 2022
-20.77M
Maximum
Dec 2020
-72.11M
Average
-84.12M
Median
Dec 2023
Cash from Operations (TTM) Benchmarks
| Affimed NV | -119.38M |
| InflaRx NV | -40.94M |
| MorphoSys AG | -- |
| BioNTech SE | 5.815B |
| Immatics NV | 19.73M |